Javascript was detected to be disabled. Javascript is required for some functions on this website.

The Institute for Innovation & Valuation in Health Care, InnoValHC, is an independent not-for-profit research organization. It was established by scientists with medical, health economic, and econometric backgrounds, as well as hands-on management experience, to analyse health economic and treatment strategies (see Profile). Learn more about the institute's Purpose and Projects.

News

Invitation to Stakeholders concerned with Economic Evaluation and Health Technology Assessments (HTAs)

Announcement: Heidelberg Health Economics Summer School 2016

Dear Colleague:

Following the positive feedback we received regarding last year’s Health Economics Summer School, we decided to offer a new program in 2016.

Read more …

Heidelberg Health Economics Summer School 2016

A program offered by InnoValHC in cooperation with the University of Heidelberg,
Mannheim Institute of Public Health (Mannheim Medical Faculty),

September 19-21, 2016: Essential Modeling Techniques for Cost Effectiveness Analysis (Workshop)
September 26-28, 2016: Health Care Payers’ & Policy Makers’ Forum (Current & Future Expectations)

The number of participants will be limited to facilitate an intense exchange with faculty, presenters, and colleagues. We therefore recommend early registration. For more information, please contact us at academy(at)innoval-hc.com.

Read more …

The Social Value of Orphan Medicinal Products

Now online available: First public presentation and discussion of the European Social Preference Measurement (ESPM) project at the Multi-Stakeholder Symposium on improving patient access to rare disease therapies, organized by “Rare Diseases Europe” (EURORDIS) in Brussels, February 24, 2016.

Read more …

Impressions from Heidelberg Health Economics Summer School 2015 Online

Scientists and stakeholders sharing an interest in the economic evaluation of health and health care met again in Heidelberg in September 2015, to spend a week full of exchange and debate. They addressed a wide range of topics mainly related to the appropriate use of economic analyses to inform Health Technology Assessments, spanning conceptual foundations, current issues and recent developments in North America, Australia, and Europe. A pictorial record capturing the stimulating atmosphere at the 2015 Heidelberg Health Economics Summer School has now been made available online.

Read more …

Can We Afford the Cost of Cancer Care?

Health care policy makers are increasingly worried by the increasing costs of cancer care. In particular, the average costs per patient of some new cancer treatments now exceed €10,000 per month. The inevitable concern about the future affordability of these treatments is aggravated by the fact that some of them have not even been shown to increase overall survival by any relevant margin – in fact, some of them improve progression-free survival only. On the one hand, almost 2.5 million people are newly diagnosed with cancer in the European Union each year, and the cost of cancer in Europe has been estimated to exceed 125 billion per year. On the other hand, substantial medical progress has been achieved in some areas, and research promises further improvements by targeting interventions using genetic information.

Against this background, a presentation at the German Cancer Research Center addressed key issues related to the future affordability, as well as measures taken internationally to ensure value for money, of cancer care.

Also see Recent Scientific Presentations.

Read more …